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but declines postnatally to low levels in the adult (Malosio et al., 
1991; Watanabe and Akagi, 1995). The β subunit, which shows a 
surprisingly widespread distribution throughout the spinal cord 
and the brain, also increases with age in parallel with the α1 and 
α3 subunits.
Inhibitory synaptic transmission in motor reﬂ  ex circuits of the 
spinal cord is mediated by the α1β GlyR. This is perhaps best evi-
denced by the fact that hereditary mutations to the α1 GlyR that 
reduce the charge transfer rate of synaptic α1β GlyRs cause human 
startle disease, a disorder characterized by a temporary increase 
in muscular rigidity but no alteration in cognitive state (Bakker 
et al., 2006).
The retina expresses a diversity of GlyR subunits. Synaptic 
GlyRs comprising α1β, α2β and α3β GlyRs are all postulated to be 
present in anatomically discrete locations, although their individual 
  contributions to visual processing are yet to be elucidated (Balse 
et al., 2006; Ge et al., 2007; Grunert and Wassle, 1993; Grunert 
and Ghosh, 1999; Haverkamp et al., 2003, 2004; Jusuf et al., 2005; 
Majumdar et al., 2007; Veruki et al., 2007). The α2 GlyR subunit 
also plays a crucial role in rod photoreceptor development (Young 
and Cepko, 2004). Glycinergic synapses also are found in several 
brainstem nuclei, particularly those of the central auditory path-
ways (Caspary et al., 2008), where the large fast glycinergic synap-
tic currents are important for the precise timing associated with 
directional hearing (Kandler, 2004). Extrasynaptic GlyRs are widely 
SUBUNIT COMPOSITION, DISTRIBUTION AND FUNCTION
The inhibitory glycine receptor (GlyR) is a member of the Cys-loop 
ligand-gated receptor family that also includes the nicotinic acetyl-
choline receptor (nAChR), the GABA type-A receptor (GABAAR) 
and serotonin type-3 receptor (5-HT3R). Receptors of this class 
comprise ﬁ  ve subunits arranged symmetrically around a cen-
tral ion-conducting pore. Each subunit comprises four α-helical 
transmembrane domains and a large extracellular amino-terminal 
domain that harbours the ligand binding sites and the signature 
‘Cys-loop’ (Unwin, 2003; Hilf and Dutzler, 2008). A total of ﬁ  ve 
GlyR subunits have been identiﬁ  ed so far, namely α1−α4 and β 
(Betz and Laube, 2006; Lynch, 2009). The α4 gene is a pseudo-gene 
in humans (Simon et al., 2004). All α subunits can form functional 
homomeric receptors but β subunit is functionally expressed only 
as a heteromer with the α subunit in a putative 2α:3β stoichiometry 
(Grudzinska et al., 2005).
In the adult rat, α1 subunit mRNA is abundant in brain stem, 
spinal cord and retina but is also found in superior and   inferior 
colliculi, thalamus and hypothalamus (Malosio et  al., 1991). 
Expression is low prenatally but increases from birth to reach 
to a maximum by the end of the third postnatal weak. The dis-
tribution and developmental proﬁ  le of the α3 subunit is similar 
but occurs at lower levels, except in retina and spinal cord as 
discussed below (Malosio et al., 1991; Watanabe and Akagi, 1995). 
In contrast, the α2 subunit is present at high levels prenatally 
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distributed throughout the adult nervous system in areas such as 
the cortex (Flint et al., 1998), hippocampus (Mori et al., 2002) and 
basolateral amygdala (McCool and Farroni, 2001) where they are 
thought to mediate tonic inhibition. GlyR expression is not limited 
to neurons but is also found in sperm where GlyRs contribute to 
the acrosomal reaction that fuses sperm to the egg (Meizel, 1997). 
GlyRs have also been identiﬁ  ed in macrophages and leucocytes 
where they are thought to mediate the anti-inﬂ  ammatory effects 
of glycine (Gundersen et al., 2005).
THERAPEUTIC POTENTIAL OF GlyRs
MOVEMENT DISORDERS
As α1β GlyRs control the excitability of spinal motor neurons, 
agents that increase current ﬂ  ow through α1-containing GlyRs 
should decrease the activity of these neurons. Thus, α1-speciﬁ  c 
enhancing agents may be useful as treatments for startle dis-
ease and as muscle relaxants for hypertonic movement disor-
ders such as spasticity. Such movement disorders are currently 
treated with GABAAR-enhancing benzodiazepines which have 
substantial side-effects due to the widespread distribution of 
target GABAARs throughout the brain. In contrast, their rela-
tively limited distribution renders α1β GlyRs a more promising 
therapeutic target.
ANTI-INFLAMMATORY ANALGESIA
GlyR α1 and α3 subunits co-exist in individual glycinergic inhibi-
tory synapses on nociceptive sensory neurons in the spinal cord 
dorsal horn (Harvey et al., 2004). An inﬂ  ammatory mediator, pros-
taglandin E2 acting at the EP2 receptor, speciﬁ  cally inhibited both 
glycinergic inhibitory postsynaptic currents (IPSCs) in pain sen-
sory neurons (Ahmadi et al., 2002; Harvey et al., 2004) and glycine-
gated currents in recombinantly expressed α3 (but not α1) GlyRs 
(Harvey et al., 2004), implying that inﬂ  ammatory pain sensitisa-
tion is mediated by inhibition of glycinergic IPSCs. Consistent with 
this, knockout of either the α3 GlyR subunit or the EP2 receptor in 
mice abolished pain sensitisation induced by peripheral inﬂ  amma-
tion (Harvey et al., 2004; Reinold et al., 2005). Thus, inﬂ  ammatory 
pain sensitization is caused by a PGE2-mediated down-regula-
tion of α3-mediated glycinergic IPSCs in nociceptive neurons. 
This in turn implies that molecules that can speciﬁ  cally potenti-
ate or prolong IPSCs in spinal nociceptive neurons offer prom-
ise as anti-inﬂ  ammatory analgesic lead compounds. Although it 
should be possible to compensate for the effects of inﬂ  ammatory 
mediators on α3-containing GlyRs by pharmacological enhance-
ment of charge transfer through synaptic α1-containing GlyRs, 
the risk of side-effects is higher given that α1 subunits are more 
widespread outside the dorsal horn (Lynch and Callister, 2006; 
Zeilhofer, 2005).
IMMUNOMODULATION
Functional GlyRs are present in immune cells including neu-
trophils (Wheeler et al., 2000), macrophages and leucocytes (Froh 
et al., 2002; Ikejima et al., 1997). There is mounting evidence that 
GlyRs in these cells mediate the anti-inﬂ  ammatory and cytopro-
tective actions of glycine by antagonising the intracellular cal-
cium increases that mediate the activation of these cells (Froh 
et al., 2002; Ikejima et al., 1997). Thus, by inhibiting the activity 
of immune cells, the systemic administration of glycine or GlyR 
potentiating agents could limit the damage inﬂ  icted by the systemic 
 inﬂ  ammatory immune response on essential biological molecules, 
cells and organs (Gundersen et al., 2005).
TEMPORAL LOBE EPILEPSY
RNA-edited high afﬁ  nity α2 and α3 GlyR transcripts were found 
to be upregulated in patients suffering from temporal lobe epilepsy 
(Eichler et al., 2008, 2009). In the same patients, transcript levels of 
the potassium chloride co-transporter type-2 (KCC2) were found 
to be downregulated. To determine whether these alterations may 
lead to temporal lobe epilepsy, the effects of changes in expression 
levels of the respective transcripts were investigated using a neuro-
nal culture system. As expected, upregulation of high afﬁ  nity GlyRs 
and downregulation of KCC2 resulted in depolarising tonic GlyR 
activity which shunted excitatory inputs, and rendered GABAergic 
synapses excitatory. This in turn led to an increased glutamatergic 
to GABAergic synapse ratio and a reduction in dendrite lengths 
and excitotoxicity, thus providing a possible mechanism for the 
increased neuroexcitability associated with temporal lobe epilepsy 
(Eichler et al., 2008).
THE CASE FOR DISCOVERING NOVEL GlyR MODULATORS
Novel GlyR subtype-speciﬁ  c potentiating agents are required as 
therapeutic lead compounds for epilepsy, movement disorders, 
chronic inﬂ  ammatory pain and immunomodulation. On the 
other hand, antagonists speciﬁ  c for high afﬁ  nity α2 and α3 GlyRs 
may be useful as therapeutic leads for temporal lobe epilepsy. 
In addition to clinical leads, subunit-speciﬁ  c pharmacological 
probes are also needed for establishing the presence and establish 
the roles of different GlyR isoforms in central nervous system 
regions (e.g., retina and spinal cord dorsal horn) that express a 
diversity of GlyR subtypes. Often the simplest way of identifying 
the presence and physiological role of a particular ion channel 
subtype is to use an isoform-speciﬁ  c inhibitor to eliminate its 
contribution to the complex suite of conductances active at any 
one time in a neuron.
Unfortunately, almost all known GlyR modulators also have 
potent effects on other receptor types (Lynch, 2009) which limit 
their utility as probes for establishing the physiological role of dif-
ferent GlyR subtypes. Importantly, there are no compounds known 
to potentiate α3 GlyRs while having no effect on α1 GlyRs. Thus, 
the development of novel GlyR subunit-speciﬁ  c pharmacological 
probes is long overdue. To date there have been few, if any, published 
investigations describing systematic attempts to identify novel GlyR 
subtype-speciﬁ  c modulators.
Given the unusually high (>90%) amino acid sequence identity of 
α1 and α3 GlyR subunits in their extracellular and transmembrane 
receptor domains, it is relevant to consider whether pharmacologi-
cal agents are likely to be found that discriminate strongly between 
these isoforms. Fortunately, there are two indications to suggest that 
such ligands may eventually be identiﬁ  ed. First, using chimeras of α1 
and α3 subunits, we identiﬁ  ed the structurally divergent M4 trans-
membrane segment as a speciﬁ  c determinant of the large agonist 
efﬁ  cacy difference between these two subtypes (Chen et al., 2009b). 
This suggests that the lipid-exposed M4 domain may be a promising 
region for subtype-speciﬁ  c modulators to bind. Second,  anandamide, Frontiers in Molecular Neuroscience  www.frontiersin.org  October 2009  | Volume 2  |  Article 17  |  3
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N-arachidonyl-glycine and several synthetic cannabinoid agonists 
exhibit distinct pharmacological actions on α1 and α3 GlyRs (Yang 
et al., 2008). For example, WIN55,212-2 has no effect on α1 GlyRs 
but potently inhibits α3 GlyRs. Although the location of the can-
nabinoid   binding site is not yet known, these ﬁ  ndings bode well for 
the existence of pharmacologically distinct modulatory sites on α1 
and α3 GlyRs.
TECHNIQUES FOR DISCOVERING NEW GlyR-ACTIVE DRUGS
AUTOMATED PATCH-CLAMP ELECTROPHYSIOLOGY
Patch-clamping is the deﬁ  nitive means of assaying ion channel 
function. It not only offers an unparalleled signal-to-noise ratio 
but also tracks the effects of compounds in real time. This later 
feature permits complex effects of compounds (e.g., fast potentia-
tion followed by slow inhibition) to be resolved. Several automated 
patch-clamp technologies have been successfully implemented 
(Finkel et al., 2006; Lepple-Wienhues et al., 2003; Mathes et al., 
2009; Milligan et al., 2009). Although the technology is advanc-
ing steadily in terms of reliability, throughput and cost, it is still 
limited by high cost and modest throughput (Dunlop et  al., 
2008). Thus, automated patch-clamp is probably best deployed 
as a means of conﬁ  rming and quantitating the activity of com-
pounds discovered by ﬂ  uorescent assays (see below). Because 
automated patch-clamp technologies select cells at random for 
screening, it is generally necessary to create stable cell lines where 
all cells express the ion channels of interest in order to optimize 
data acquisition. Stably expressing cell line creation can be a slow, 
painstaking process, especially when one is interested in screening 
multimeric receptors.
RADIOACTIVE ASSAYS
These can be separated into radioligand displacement assays and 
radiotracer ﬂ  ux assays. In the case of GlyRs, radioligand displace-
ment assays involve displacing 3H-strychnine with unlabelled test 
compound (Young and Snyder, 1973). There are several limita-
tions to this technology. First, it provides no information about the 
mode of action (if any) of a compound. Second, it may not detect 
compounds that modify receptor function without displacing the 
radioligand. Finally, long incubations with agonists may promote 
a desensitised state with different pharmacology to the normal 
resting closed or activated states (Changeux and Edelstein, 1998). 
Radioactive tracer ﬂ  ux assays detect the transmembrane ﬂ  ux of 
the radioactive anions, 125I− or 36Cl− (Kardos, 1993; Venglarik et al., 
1990). I− is highly permeant through GlyRs (Fatima-Shad and Barry, 
1993). Being an assay of receptor function rather than binding, 
this technique overcomes some of the limitations of radioligand 
displacement assays. In general, radioactive assays are not optimal 
for high throughput (HT) drug discovery due to long incubation 
times and multiple processes (e.g., tracer loading, cell-wash and 
cell lysis steps) that limit HT, the high cost of materials, and the 
inconvenience associated with safe handling and disposal of radio-
active materials.
COLORIMETRY
Transmembrane I− inﬂ  ux can be measured via a change in colour 
of a non-ﬂ  uorescent cytoplasmic indicator (Tang and Wildey, 
2004). The rate of accumulation of intracellular I−, and hence 
cell colour, will depend on the degree to which the channels are 
activated. Because all reactions will eventually proceed to steady-
state   regardless of the agonist concentration, it is necessary to 
control the length of time that the reaction is allowed to proceed. 
This assay has the advantage of low cost and avoids the safety 
and environmental issues associated with radioactive materials. 
However, as with the radioactive tracer ﬂ  ux assay, its utility is 
limited by the requirement for tracer loading, cell wash and lysis 
steps. An analogous approach, in which Cl− inﬂ  ux precipitated an 
excess of intracellular Ag+ ions leading to a colour change (Gill 
et al., 2006), may suffer the same limitations.
VOLTAGE SENSITIVE DYES (VSDs)
A wide range of VSDs is commercially available and the choice gen-
erally involves a trade-off between speed of response and dynamic 
range. In HT screening (HTS) applications, dynamic range is 
the prime consideration. A ﬂ  uorescent membrane potential dye 
(marketed by Diagnostic Instruments Inc.) has successfully been 
employed to screen compounds against α1 GlyRs stably expressed 
in HEK293 cells (Jensen and Kristiansen, 2004). In that study, ionic 
gradients were established such that GlyR activation induced a 
depolarisation and a consequent increase in ﬂ  uorescence. The dye 
response was relatively slow, taking at least 30 s to reach steady-state, 
but it offered an excellent dynamic range.
High response speed and dynamic range can be simultaneously 
achieved using ﬂ  uorescence resonance energy transfer (FRET). 
This technique involves the non-radiative transfer of energy from 
a donor ﬂ  uorophore to an acceptor ﬂ  uorophore provided the donor 
emission spectra and acceptor absorption spectra overlap and the 
respective ﬂ  uorophores are in close proximity. When the donor 
is excited at its absorption wavelength, FRET causes the   acceptor 
ﬂ  uorescence to increase and donor ﬂ  uorescence to decrease. It has 
been shown that a donor, CC2-DMPE, and an acceptor, DiBac2, 
produce a robust FRET at negative membrane potentials when 
both lie at the external membrane surface (Gonzalez and Tsien, 
1997). Upon depolarisation, DiBac2 crosses the membrane thereby 
increasing its distance from CC2-CPMPE and decreasing FRET 
efﬁ  ciency. The subsequent ﬂ  uorescence change occurs rapidly over 
a large dynamic range. This method has successfully been used 
to screen GABAARs (Adkins et al., 2001) and GluClRs (Hamelin 
et al., 2005). In both cases, cells were bathed in low-Cl- buffer so 
that GABAAR activation induced a Cl- efﬂ  ux leading to depolarisa-
tion. This technique provides a rapid and sensitive indication of 
anionic receptor activation. However, the technique is expensive as 
it requires two exogenous ﬂ  uorescent indicators. Also, because the 
plasma membrane concentrations of the respective ﬂ  uorophores 
must be optimised individually for maximum FRET efﬁ  ciency, this 
technique may require two dye incubation steps.
As a general point, exogenously applied dyes have several limi-
tations. First, they constitute a signiﬁ  cant recurrent expense and 
second, they require dye loading and (sometimes) cell-wash steps 
that limit HT. Third, and perhaps most seriously, lipophilic dyes 
are taken up by all cells regardless of whether or not they express 
the ion channel of interest. If, for example, only half the cells 
express the ion channel of interest then the dynamic range of the 
averaged ﬂ  uorescence response is halved. Thus, to achieve its full 
dynamic range, all cells must respond to the dye. This requirement Frontiers in Molecular Neuroscience  www.frontiersin.org  October 2009  | Volume 2  |  Article 17  |  4
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means that techniques involving exogenously applied indicators 
are suited primarily to homogeneous assays such as those involv-
ing stably expressing cell lines.
GENETICALLY ENCODED ANION INDICATOR
Yellow ﬂ uorescent protein (YFP), an engineered variant of green 
ﬂ   uorescent protein, is quenched by small anions and is thus 
suited to reporting anionic inﬂ  ux into cells. A random mutagen-
esis approach identiﬁ  ed two mutations, I152L and V163S, each 
of which greatly enhanced YFP anion sensitivity (Galietta et al., 
2001a). The I152L mutation confers a particularly high sensitivity 
to I− quench (Ki ∼ 3 mM). YFP-I152L has proved useful in screening 
compounds against the anion-conducting cystic ﬁ  brosis transmem-
brane regulator (Galietta et al., 2001b; Yang et al., 2003). It has also 
been applied to the GlyR and GABAAR (Kruger et al., 2005). This 
assay has several advantages over the VSD assay. First, although 
both assays have similar signal-to-noise ratios and dynamic ranges, 
the YFP assay is faster by a factor of at least three in achieving 
a given percentage ﬂ  uorescence change (Jensen and Kristiansen, 
2004; Kruger et al., 2005). Second, as a propagable substance, YFP 
cDNA is cheaper. Third, the simultaneous transfection of YFP and 
ion channel cDNAs in separate plasmid vectors results in a high 
rate of transient co-expression of YFP and functional recombinant 
channels (Kruger et al., 2005). Thus, the YFP-based assay does not 
require stably expressing cell lines to achieve its full dynamic range. 
Finally, as a genetically encoded probe, YFP is also suited to screen-
ing heterogeneous populations of isolated neurons where the YFP is 
transgenically expressed in a deﬁ  ned subset of cells. If an  imaging-
based detection system is used, this assay would also be suitable for 
‘high-content’ screening (i.e., the correlation of multiple variables 
in the same cell). As an example of this, we have recently dem-
onstrated the feasibility of screening a single compound against 
numerous GlyR receptor subtypes simultaneously via the YFP assay 
by using cell-permeant dyes to provide cells expressing a given 
receptor with a unique optical identiﬁ  er (Gilbert et al., 2009c).
Although genetically encoded ﬂ  uorescent detectors of mem-
brane potential are steadily being improved, at this stage their maxi-
mum voltage-induced ﬂ  uorescence changes are typically <10% of 
the resting ﬂ  uorescence level (Baker et al., 2008; Perron et al., 2009). 
This narrow dynamic range may be too small to yield robust rea-
douts during HTS, and may explain why these probes have yet to 
be broadly implemented as drug discovery tools.
GlyR DRUG DISCOVERY IN OUR LABORATORY
YFP-BASED PRIMARY SCREENING
Our laboratory employs YFP for primary HTS of large compound 
libraries or natural product fractions. For this purpose we have con-
structed a custom built robot comprising an inverted ﬂ  uorescence 
microscope, an automated stage, an autosampler for liquid handling 
and a digital camera all under the control of Labview (National 
Instruments Corp, Austin, TX, USA) programs. The components 
of this device have previously been described in detail (Kruger et al., 
2005). Experiments are performed on adherent HEK293 cells in 
384 well plates. The autosampler can deliver up to three different 
solutions (with or without removing the previous solution) from 
different sources to a single well, thus providing a wide range of 
liquid handling options. Although multiple solution exchanges in 
single wells is useful for assay development, we avoid it for HTS as 
it slows the screening process too much. The CCD captures images 
like those in Figure 1A and image analysis is automated using cus-
tomized DetecTiff© software (Gilbert et al., 2009b). VSD and YFP 
screening technologies have also been successfully employed with 
commercial ﬂ  uorescent plate readers (Jensen and Kristiansen, 2004; 
Kruger et al., 2005).
To prepare cells for experiments, we simultaneously transfect 
HEK293 cells with cDNAs for YFP-I152L plus the GlyR clone of 
interest. We have recently published a detailed comparison of ﬁ  ve 
transient transfection methods employed routinely in the laboratory 
for this purpose (Gilbert et al., 2009a). Once transfection is com-
pleted and the transfection reagent has been removed, around 2000 
cells, suspended in 40 µl culture media, are plated into each well of a 
384-well plate. Plates are then returned to the incubator and used for 
experiments 24–72 h later. Based on the proportion of ﬂ  uorescent 
cells, transfection efﬁ  ciency varies from 10 to 50%. As only those 
cells near the centre of the well are imaged, we are typically restricted 
to analysing 100–500 ﬂ  uorescent cells per well (∼1000 cells total per 
image). As noted above, we routinely achieve an excellent correlation 
between cells expressing YFP and cells expressing GlyRs.
Sample images of cells expressing YFP-I152L and α1 GlyRs are 
shown in Figure 1A. Imaged cells in the top and bottom rows were 
exposed to NaCl and NaI solutions, respectively. The images in 
the bottom rows were taken after an 8 s exposure to either NaI alone 
(bottom left panel) or NaI plus 1 mM glycine (bottom right panel). 
Figure 1B quantitates the percentage ﬂ  uorescence change produced 
by the addition of glycine. Percentage ﬂ  uorescence change is deﬁ  ned 
as [(Fﬁ  nal/Finit) − 1) × 100 where Finit and Fﬁ  nal are the initial and ﬁ  nal 
values of ﬂ  uorescence, respectively. The experiment demonstrates 
that the YFP assay provides a robust indication of GlyR activation. To 
underscore this point, a sample experimental analysis output screen 
of a glycine dose–response experiment is shown in Figure 1C. The 
green histograms indicate the number of ﬂ  uorescent cells in each of 
24 wells in a single row of a 384-well plate. The blue columns show 
the number of cells that displayed a >20% quench in response to 
the addition of control NaI plus glycine at the indicated concentra-
tions. Each concentration was added to two adjacent wells, with con-
centrations increasing from left to right as indicated in Figure 1C. 
This panel shows that almost all ﬂ  uorescent cells displayed >20% 
quench at saturating glycine concentrations, supporting previous 
evidence for a strong correlation between YFP and GlyR expression. 
Figure 1D shows an alternative analysis of the results presented in 
Figure 1C, this time plotting mean percentage ﬂ  uorescence change 
of all ﬂ  uorescent cells against glycine concentration.
To demonstrate the robustness of this assay, Figure 1E shows a 
sample outcome of an actual screening experiment. In this experi-
ment, cells were pre-incubated with either no compound (‘nega-
tive control’ in wells 1 and 2), 10 µM of the antagonist strychnine 
(‘positive control’ in wells 23 and 24) or a natural product frac-
tion with each fraction plated into two adjacent wells (wells 3–22). 
A control image was taken prior to glycine addition and a test image 
was taken 8 s after glycine addition. The mean percentage ﬂ  uores-
cence change for all cells in each well was calculated as described 
above and translated into a colour according to the scale shown in 
Figure 1E. Thus, the ‘warmer’ the colour, the greater the antago-
nist activity. This experiment yielded two strong hits as shown in Frontiers in Molecular Neuroscience  www.frontiersin.org  October 2009  | Volume 2  |  Article 17  |  5
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orange, and a weaker hit as shown in green. We initially screen 
natural product fractions as antagonists as the dynamic range of 
an antagonist   ﬂ  uorescence response is typically much larger than 
it is for a potentiator response. Once a high afﬁ  nity antagonist is 
identiﬁ  ed, we isolate and screen analogues of this compound by 
automated patch-clamp electrophysiology to ﬁ  nd subunit-speciﬁ  c 
positive and negative modulators.
Using this assay we have screened around 3000 natural product 
fractions against α1 GlyRs, yielding 27 active fractions. From these 
fractions we have identiﬁ  ed at least four compound families with 
strong GlyR subunit-speciﬁ  c potentiating and   inhibitory effects. 
From active fractions, we have so far identiﬁ  ed 28   compounds with 
potent (nanomolar – low micromolar) effects on GlyRs as follows:
•  12 compounds that speciﬁ  cally potentiate α1 GlyRs,
•  1 compound that speciﬁ  cally potentiates α3 GlyRs,
•  2 compounds that potentiate both α1 and α3 GlyRs,
•  1 compound that speciﬁ  cally inhibits α1 GlyRs,
•  4 compounds that speciﬁ  cally inhibit α3 GlyRs and
•  8 compounds that inhibit both α1 and α3 GlyRs.
FIGURE 1 | Screening GlyRs using YFP -I152L. (A) Images in the upper row 
were recorded in NaCl control solution whereas images in the lower row were 
recorded from the same wells 8 s after replacement with NaI alone (left image) 
or NaI + 1 mM glycine (right image). (B) Cell ﬂ  uorescence distribution for 
experiments shown in (A). The ‘% ﬂ  uorescence change’ is deﬁ  ned in the text. 
(C) Glycine dose–response as revealed by YFP ﬂ  uorescence change. Each 
green histogram represents the total number of imaged ﬂ  uorescent cells in a 
single well of a 384-well plate. Blue histograms represent the number cells per 
well that quenched by >20% upon glycine addition. From left, glycine 
concentrations were (in µM): 0, 3, 10, 15, 30, 50, 100, 300, 1000, 3000. Each 
was applied to two wells and every second value is shown. (D) Mean 
percentage ﬂ  uorescence change of all ﬂ  uorescent cells in (C) plotted against 
glycine concentration. Fitted EC50 = 22 µM. (E) ‘Heatmap’ of an actual 
screening experiment comprising eight rows of a 384-well plate, with ‘hits’ (i.e., 
fractions producing antagonistic activity) boxed and labelled. Experimental 
design is described in the text.Frontiers in Molecular Neuroscience  www.frontiersin.org  October 2009  | Volume 2  |  Article 17  |  6
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GENERATING STABLY EXPRESSING HEK293 CELL LINES
As automated patch-clamp electrophysiology requires stable cells 
lines expressing the channels of interest, we generated cell lines 
that stably express either α1 or α3 GlyRs. For this purpose, both 
human α1 and α3 GlyR subunit cDNAs were cloned into the 
pcDNA3.1 plasmid vector. Following transfection with linearised 
vector DNA, HEK293 cells were maintained for 14–21 days in 
selection medium containing 1 mg/ml of the selection antibi-
otic, G-418, and 10 µM strychnine. The strychnine was required 
to prevent the glycine in the culture medium from activating 
the GlyRs. The surviving cells were trypsinised, counted and 
diluted, so as to yield a suspension that was used to plate (on 
average) one individual clone into each well of several 96-well 
plates. Individual clones were then grown in the same selection 
medium for about 2 weeks. All wells identiﬁ  ed as containing 
monoclonal colonies were screened for a functional response to 
1 mM glycine using the YFP assay. In this screening several cell 
clones transfected with either α1 or α3 GlyR subunits exhibiting a 
signiﬁ  cant response to glycine exposure were identiﬁ  ed and then 
the selection process described above was repeated using these 
clones. Finally, after further testing, cells were split into 24-well 
plates, 6-well plates, 6 cm dishes and T75 ﬂ  asks successively. All 
remaining clones were frozen at −80°C for later use. Clones of 
each subunit were then selected for further characterization in 
the patch-clamp and YFP assay.
AUTOMATED PATCH-CLAMP ELECTROPHYSIOLOGY
These recordings were performed using a Nanion Patchliner 
automated planar chip patch-clamp device (NPC-16A, Nanion 
Technologies GmBH, Munich, Germany). This device employs 
expendable planar glass ‘chips’ each consisting of a glass plate 
with 16 apertures embedded into a perspex microﬂ  uidic system 
which directs solutions to the internal and external sides of each 
aperture. The tiny volume of this microﬂ  uidic system is a major 
advantage of this system as it allows experiments to be conducted 
with extremely small quantities of compounds. For example, the 
external solution bathing the cells can be completely exchanged 
using 25 µl of new solution. Although chips permit 16 single cell 
recordings, only eight can be made simultaneously. The ﬁ  rst step 
in forming the whole cell conﬁ  guration is to inject a suspension of 
stably expressing cells into the microﬂ  uidic system thereby plac-
ing them at the external aperture surface. Then, by application of 
negative pressure to the opposite side of the aperture, a single cell 
is attached at random to the aperture. Contrary to the classical 
patch-clamp technique, it is the cell that is moved to the aperture 
and not the pipette that is moved to the cell. As with conventional 
patch-clamp, a seal is obtained by the application of suction in 
an automated manner and the membrane is then ruptured for 
whole cell access. The result is a low resistance electrical pathway 
to the inside of the cell allowing for whole cell patch-clamp record-
ings. Full experimental details of these standardized procedures, 
including compositions of internal and external solutions, are 
provided in recent reviews (Bruggemann et al., 2008; Farre et al., 
2009; Milligan et al., 2009).
Sample glycine dose–response relationships from HEK293 cells 
stably expressing either α1 or α3 GlyRs recorded using the pla-
nar chip device are shown in Figure 2. The current recordings are 
comparable in quality to those generated by conventional patch-
clamp and the glycine EC50 values generated using the planar chip 
device are comparable with those recorded in our laboratory using 
conventional electrophysiology (Figure 2, legend). This suggests 
that both the stably expressing cell lines developed in our labo-
ratory and the planar chip recording system are appropriate for 
quantitating the sensitivity of α1 and α3 GlyRs to compounds 
of interest. Indeed, we have used this device to generate averaged 
dose–response relationships for a total 36 compounds of interest at 
α1 and α3 GlyRs, each averaged from 3 to 8 cells. In broad agree-
ment with a previous study (Milligan et al., 2009), we typically 
experience a whole-cell recording success rate of around 80% of 
all cells sucked onto the aperture, with around 50% of recordings 
lasting for 10 min or more.
FIGURE 2 | Planar whole-cell patch-clamp data from HEK293 cells stably 
expressing α1 or α3 GlyRs. (A) Current responses in cells expressing α1 and 
α3 GlyRs. Indicated glycine concentrations were applied for 2 s at 1 min 
intervals. (B) Averaged glycine dose–responses averaged from ﬁ  ve cells 
expressing either α1 (ﬁ  lled symbols) or α3 GlyRs (unﬁ  lled symbols). Error bars 
represent standard errors and curves are Hill equation ﬁ  ts to the averaged 
data. Individual α1 GlyR dose–response curves were ﬁ  tted a mean glycine 
concentration of 24 ± 2 µM and a Hill coefﬁ  cient of 1.9 ± 0.2 (n = 5 cells). Both 
values were not signiﬁ  cantly different to their respective means (30 ± 1 µM 
and 1.7 ± 0.2, n = 5) recorded by conventional patch-clamp of HEK293 cells 
transiently expressing α1 GlyRs (Chen et al., 2009a). The α3 GlyR dose–
responses were ﬁ  tted with a mean glycine concentration of 166 ± 9 µM and a 
Hill coefﬁ  cient of 1.4 ± 0.1 (n = 5 cells). In contrast, the respective mean 
values for α3 GlyRs recorded by patch-clamp of transiently transfected 
HEK293 cells were 309 ± 20 µM and 2.0 ± 0.1 (n = 5) (Chen et al., 2009a).Frontiers in Molecular Neuroscience  www.frontiersin.org  October 2009  | Volume 2  |  Article 17  |  7
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DISCOVERY OF NOVEL GlyR DRUG BINDING SITES BY 
SCREENING RANDOM MUTANT LIBRARIES
CREATION AND SCREENING OF A GlyR RANDOM MUTANT LIBRARY
It is not always possible to identify novel drug binding sites using 
site-directed mutagenesis. For example, at the GlyR it has not yet 
proved possible to identify the binding site for the non- glycinergic 
agonist, ivermectin. We are interested in identifying its binding 
site because, (1) it is commonly used as an anti-parasitic in agri-
culture, veterinary and human medical practice (Omura, 2008) 
and (2) it activates the GlyR by a mechanism distinct from glycin-
ergic agonists (Pless et al., 2007) and thus may prove a useful tool 
for probing GlyR activation mechanisms. One way of discovering 
this and other intractable binding sites is to use HT methods to 
screen the drug of interest against a large library of randomly 
mutated GlyRs.
Random mutagenesis methods generally involve error-prone 
PCR and a range of strategies for implementing this approach have 
been developed (An et al., 2008; Emond et al., 2008; Fujii et al., 
2006). The approach we used was to create a library of randomly 
mutated α1 GlyR-pcDNA 3.1 clones using the GeneMorph II 
Random Mutagenesis Kit (Stratagene). Following manufacturers’ 
instructions, fragment PCR reaction conditions were optimized 
(750 ng template and 30 cycles of PCR) to yield a mutation fre-
quency of one to two mutations per 1000 base pairs (15–20 clones 
from each PCR reaction were sequenced, covering more than 
10,000 bp). The observed mutational spectra, which closely resem-
bled that predicted for Mutazyme II, corresponded to one to three 
amino acid changes per receptor. The observed amino acid changes 
were scattered throughout the entire coding sequence with no evi-
dence of clustering. Approximately 20–25% of the sequenced clones 
contained no mutations. A similar mutation rate was successfully 
employed in a similar screen of the TRPM8 channel (Bandell et al., 
2006). As this was deemed an appropriate mutation rate, we then 
used a commercial service (Australian Genome Research Facility, 
Brisbane, QLD, Australia) to grow 1536 clones derived from the 
same PCR reaction in 384-well format and then extract plasmid 
DNA of sufﬁ  cient quality. A glycerol stock of each clone was also 
made. This process resulted in an average yield of around 100 ng 
plasmid DNA per clone.
Since all transfection procedures of which we are aware use at 
least 100 ng plasmid DNA regardless of cell number or culture 
media volume, it was necessary to develop a technique of reli-
ably transfecting much smaller amounts of plasmid DNA into 
single wells of a 384-well plate. This technique is presented in 
the Supplementary Material. In brief, we scaled down a standard 
calcium phosphate transfection procedure and tested its transfec-
tion efﬁ  ciency with differing amounts of YFP plasmid DNA. As 
shown in Figure 3, the YFP transfection efﬁ  ciency was found to 
be maximal at 10 ng plasmid DNA per well.
In a search for mutations that affect ivermectin sensitivity, we 
ﬁ  rst added NaI containing 30 nM ivermectin to each well. This 
was followed by an application of 10 µM ivermectin and then one 
of 10 mM glycine. The rationale for this approach was that 30 nM 
ivermectin is subthreshold at the wild type (WT) α1 GlyR, whereas 
10 µM is barely saturating (Shan et al., 2001). Thus, quantitating 
variations in receptor responses to both of these concentrations 
should permit the detection of mutations that substantially increase 
or decrease ivermectin sensitivity. The ﬁ  nal saturating glycine 
application was a control to ascertain the functional expression 
of GlyRs in the event that a mutation completely eliminated iver-
mectin sensitivity.
SAMPLE RESULTS OF RANDOM MUTANT SCREEN
After a ﬁ  rst round screen of a total of 1566 clones (1536 random 
mutants plus 30 site directed mutants previously generated in 
the laboratory), we identiﬁ  ed 44 mutant clones that signiﬁ  cantly 
changed ivermectin sensitivity. The effects of 20 of these clones 
were conﬁ  rmed by a second round of ﬂ  uorescence-based screen-
ing. From this pool of clones, we have so far conﬁ  rmed by nucle-
otide sequencing and electrophysiology a total of four α1 GlyR 
FIGURE 3 | Yellow ﬂ  uorescent protein expression in cells transfected in 
single wells of a 384-well plate as a function of the amount of cDNA 
transfected. (A) Sample results from a single experiment. All wells contained 
an equivalent number (∼5000) of cells. (B) Mean number of ﬂ  uorescent cells 
per image, averaged from four independent experiments. Arrow denotes 
point of optimal transfection efﬁ  ciency.Frontiers in Molecular Neuroscience  www.frontiersin.org  October 2009  | Volume 2  |  Article 17  |  8
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  mutations that signiﬁ  cantly change ivermectin sensitivity. One of 
the   mutations identiﬁ  ed by this process was the highly conserved 
Y279F substitution in the extracellular M2-M3 linker domain. 
Examples of currents activated by the indicated concentrations of 
ivermectin and glycine in the WT and Y279F mutant α1 GlyRs are 
shown in Figure 4A. Averaged ivermectin dose–responses for both 
receptors, with current magnitudes normalised to those   activated 
by glycine in the same cell are presented in Figure 4B. An  averaged 
ivermectin dose–response for the Y279C mutant GlyR is also shown 
to indicate the speciﬁ  city of the Y–F substitution in disrupting 
ivermectin sensitivity. Because this substitution involves simply the 
removal of a hydroxyl group, we hypothesise that Y279 is speciﬁ  cally 
FIGURE 4 | The Y279F mutation dramatically reduces α1 GlyR sensitivity to 
ivermectin. (A) Conventional whole-cell patch-clamp recordings from HEK293 
cells transiently expressing unmutated or Y279F mutant α1 GlyRs (upper and 
lower panels, respectively). The indicated concentrations of glycine and 
ivermectin were applied as indicated by the unﬁ  lled and ﬁ  lled bars, respectively. 
Because ivermectin activation is irreversible, dose–responses were generated 
by successively applying increasing ivermectin concentrations. (B) Averaged 
ivermectin dose–responses each averaged from ﬁ  ve cells expressing either WT 
α1 GlyRs (ﬁ  lled circles), Y279C mutant α1 GlyRs (unﬁ  lled circles) or Y279F 
mutant α1 GlyRs (triangles). Error bars represent standard errors of the mean 
and curves represent ﬁ  ts to the averaged data with the Hill equation. The Y to F 
mutation causes an approximately 50 fold reduction in ivermectin sensitivity.Frontiers in Molecular Neuroscience  www.frontiersin.org  October 2009  | Volume 2  |  Article 17  |  9
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involved in either the binding or gating mechanism of  ivermectin. 
Experiments are currently underway to resolve the molecular basis 
of this effect. We expect these experiments may provide crucial 
insights into the binding site or mechanism of action of this impor-
tant pharmaceutical agent.
CONCLUSION
Despite GlyRs emerging as potential drug targets for therapies 
aimed at movement disorders, chronic inﬂ  ammatory pain, tem-
poral lobe epilepsy and immunomodulation, we are not aware of 
any systematic, published attempts to discover new drugs active at 
these receptors. The ﬁ  rst aim of this review was to consider various 
HTS-amenable methods that may be applicable to these receptors. 
We conclude that an anion sensitive YFP is an optimal method 
for ﬁ  rst round screening and that automated electrophysiology 
of cell stably expressing GlyRs is a useful means of conﬁ  rming 
activity and quantitating the actions of identiﬁ  ed compounds. 
The   second aim of this review was to demonstrate how these 
techniques are used in practice in our laboratory for the purpose 
of both discovering novel GlyR-active compounds and establish-
ing their mechanisms of action.
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